Cancer drug repotrectinib tested for drug interactions in healthy volunteers
NCT ID NCT07223671
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the cancer drug repotrectinib changes the levels of other medications in the body. Thirty healthy adults took repotrectinib along with several common drugs (metformin, digoxin, rosuvastatin, bupropion, flurbiprofen, and omeprazole). The goal was to see if repotrectinib affects how these drugs are processed, which helps doctors prescribe them safely together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Repotrectinib
- What this could lead to
- If successful, this study could help doctors understand how repotrectinib interacts with other medications, leading to safer dosing guidelines.
- What could go wrong
- This is an early-stage study in healthy volunteers, not patients. Results may not predict real-world interactions in people with cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Daytona Beach, Florida, 32117-5116, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults